BioMelbourne Network Progressing BioIndustry

10th-11th September. 2014 ARCS Scientific Congress
To be held at the National Convention Centre in Canberra. More

Victorian BioPortal

Looking for Something?

The Victorian BioPortal is the largest online search engine for biotechnology in Victorian with over 2,000 individual listings.

Start your search now

BioMelbourne Network

The Building Global Bridges program provides grants of between $100,000 & $500,000 to Victorian life science companies to develop partnerships with Massachusetts companies in late stage life sciences R&D projects. The program helps Victorian innovation to accelerate, access expertise, develop skills & better reach global markets and international investors. Applications close 17 September 2013.

Building Global Bridges

tinAway, a potential cure for chronic tinnitus: a crowdfunding campaign is launched to fund a clinical trial

2nd September - tinAway is an mHealth app being developed as a potential cure for chronic tinnitus A crowdfunding campaign has been launched on September 1, 2014, to support a clinical trial of the tinAway iPad app in chronic tinnitus A novel treatment that may provide a cure for chronic tinnitus is seeking support for development costs through a crowdfunding campaign. The campaign is no... read more…

PROFESSOR CHUBB RELEASES “SCIENCE, TECHNOLOGY, ENGINEERING AND MATHEMATICS: AUSTRALIA’S FUTURE”

2nd September - Professor Chubb released his recommendations for a strategic approach to science and its related fields. The document can be downloaded here “Science, Technology, Engineering and Mathematics: Australia’s Future outlines what we need to do to build a stronger, more competitive Australia,” Professor Chubb said at Parliament House. “Science is infrastructure and it is critical to... read more…

Australia’s medical research sector backs the Medical Research Future Fund

1st September - New MRFF Action Group advocates for the most important initiative in Australian medical research in generations.The organisations that carry out Australia’s world-leading medical research have joined forces to support the Federal Government’s proposed Medical Research Future Fund (MRFF). The MRFF Action Group – which comprises members from organisations representing all of Aust... read more…

Bioscience Managers Capital Return on Healthcare Fund I Locks in 24.7% IRR for Investors

28 August 2014.  Leading Australian healthcare fund manager Bioscience Managers has maintained its exceptional performance by returning capital to investors from its Australian Bioscience Fund I at 24.7% annual IRR. Since the first commitments in July 2008 the fund has called $35 million to end with $56 million returned to investors.  This corresponds to a closing unit price of $1.76 for each d... read more…

Phosphagenics Completes First IND Enabling Study for TPM®/Oxymorphone Patch

28 August 2014.  Australian drug delivery company, Phosphagenics Limited (the Company) (ASX: POH, OTCQX: PPGNY),announces that the first of its additional studies designed to further characterise the TPM®/Oxymorphone patch, in support of an Investigational New Drug (IND) application with the FDA has been completed.  The study was conducted on 15 healthy volunteers at Linear Clinical Research’s ... read more…

Pharmaceutical Executive Joins Mesoblast as Chief Financial Officer

25 August 2014 - Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the appointment of pharmaceutical executive Mr Paul Hodgkinson as Mesoblast Chief Financial Officer. Mr Hodgkinson has broad and high-level international pharmaceutical experience in allaspects of finance, strategic planning, business development and licensing,manufacturing and supply chain, and procurement. From 2011 ... read more…

BioMelbourne Network Submission - Senate Standing Committee on Economics - Inquiry into Australia’s Innovation System

31st July, 2014 - BioMelbourne Network has lodged the following submission - http://www.aph.gov.au/DocumentStore.ashx?id=92ba39b5-69b6-4dd9-a4a5-8a8ad9a9de64&subId=298526 Contact;Dr Krystal EvansChief Executive OfficerBioMelbourne Network E: kjevans@Biomelbourne.orgM: 0435 622 934 read more…

IDT Executes Binding Memorandum of Understanding with Mayne Pharma for Exclusive Distribution of Temozolomide in the US

29th July, 2014 - IDT has now secured US distribution for its generic Temozolomide product on favourable commercial terms. IDT  Australia  Limited  (ASX:IDT)  is  pleased  to  announce  that  it  has entered  into  a  binding  Memorandum  of  Understanding  (MOU)  with  Mayne  Pharma’s  US Products  division  to  distribute  IDT’s  generic  Temozolomide  product  in  the  United  States  of Am... read more…

Collaboration announced to advance malaria vaccine development

29th July, 2014 - Burnet Institute and ARTES Biotechnology have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI).The project will use exciting novel technology developed at Burnet Institute by Deputy Director, Associate Professor David Anderson and colleagues. ARTES holds the international patent rights and adapted the platf... read more…

Phosphagenics Opioid Patch Program Update

28th July, 2014 - • Next phase of the TPM®/Oxymorphone clinical development program has commenced• TPM®/Oxycodone Phase 2a trial to be conducted in Australia during Q4/2014• TPM®/Oxymorphone Phase 2 trial to be conducted in the United States in H1/2015 Australian drug delivery company, Phosphagenics Limited (“the Company”) (ASX: POH, OTCQX: PPGNY), provides the following update on its opioid t... read more…

Business Council of Australi (BCA) - Actions Needed to Build Australia’s Comparative Advantages

28th July, 2014 - Continuing Australia’s remarkable run of economic growth will require businesses and governments to take more deliberate and purposeful steps in response to global forces of change, Business Council of Australia President Catherine Livingstone said today. Ms Livingstone used her first major speech as BCA President to launch a landmark paper that recommends a radical rethink o... read more…

Dr who? Campaign to boost digital profile of Australia's female scientists

27th July, 2014 - Ever heard of Dora Lush? She was an Australian microbiologist working in the 1940s on developing a vaccine for a deadly disease known as scrub typhus. She accidentally pricked her finger with a contaminated needle. Three weeks later, she died from the very disease she was trying to tame. Hailed as a martyr for science by her contemporaries, she kept donating blood samples fro... read more…

Acrux Appoints New CEO

25th July, 2014 - Acrux (ASX: ACR) today announced the appointment of a new Chief Executive Officer and Managing Director, Mr. Michael Kotsanis. Michael is currently Chief Commercial Officer of Synthon Holding BV in the Netherlands. He has 25 years’ experience in the global pharmaceutical industry, beginning his career with Boehringer Ingelheim before moving to F. H. Faulding (which was acquire... read more…

ADMEDUS INCREASES STAKE IN IAN FRAZER’S VACCINES

24th July, 2014 -  Now owns over 66% of Admedus Vaccines  Positive interim Phase I HSV-2 data     Phase II HSV-2 programme scheduled to be initiated by end of this year Admedus (ASX: AHZ) today announced that it has increased its ownership in Admedus Vaccines, the platform vaccine development company led by Professor Ian Frazer. Over the last twelve months Admedus has increased its ho... read more…

Starpharma and Ansell Get approval for HIV-killing Condom

23rd July, 2014 - An Australian-developed virus-killing condom is a step closer to sale, following a key regulatory approval. Australian biotech firm Starpharma has developed an antiviral compound called VivaGel that laboratory tests have shown can inactivate up to 99.9 per cent of HIV, herpes and some other sexually transmitted viruses, reducing the risk of transmission. It has teamed up wit... read more…

dorsaVi to commence sale of ViMove in the US following FDA clearance

23rd July, 2014 - Wearable medical device company dorsaVi Limited (ASX: DVL) has today announced it will commence launch of ViMove in the United States following 510K clearance by the US Food and Drug Administration (FDA) for measuring, recording, and reporting on movement and muscle activity of the lower back / lumbar spine. “This is a terrific achievement for dorsaVi and opens up substantial... read more…

Phosphagenics' $19.3 million Capital Raising

11th July, 2014 - • Includes $3 million Share Purchase Plan• Upcoming opioid pain patch trials fully funded 11 July 2014, Melbourne:  Australian drug delivery company, Phosphagenics Limited (ASX:POH; OTCQX:PPGNY),has raised $19.3 million via a placement of $16.3 million to institutional and sophisticated investors in Europe, USA, Asia and Australia and $3 million from a share purchase plan (SP... read more…

Melbourne hosting the 20th International AIDS Conference (AIDS 2014)

9th July, 2014 - Participants from the biotechnology sector highlighted that Melbourne has the capability in this sector but it is challenging to promote it to potential clients who have not been to Melbourne and experienced the facilities. For international investors, seeing the facilities and the people who are part of a project is critical. Participants know that when investors visit Melbou... read more…

LBT INNOVATIONS PRESENTS RESULTS OF MOST EXTENSIVE STUDY OF LANDMARK APAS® TECHNOLOGY AT AUSTRALIAN CONFERENCE

7th July, 2014 - Australian  medical  technology  developer,  LBT  Innovations Limited  (ASX:  LBT),  yesterday presented the results of its most extensive study to date into the efficacy of its Automated Plate Assessment System (APAS®) – a breakthrough culture plate analysis system based on the company’s innovative intelligent image interpretation platform. The presentation by LBT’s Senior Mi... read more…

BioMelbourne Network Announces New CEO

4th July, 2014 - On behalf of the BioMelbourne Network board, I am delighted to announce the appointment of Dr Krystal Evans to the role of Chief Executive Officer. She will commence her full time duties in early August 2014 but will begin engagement with our members and secretariat during the month of July. Krystal is a well recognised advocate for science and technology in Australia, with a ... read more…